Adjuvant therapy for melanoma

Current Opinion in Oncology

Volumn 9, Issue 2, 1997, Pages 189-204

  Sondak, Vernon K ^a   Wolfe, Julie A ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; BCG VACCINE; BLEOMYCIN; CARMUSTINE; CISPLATIN; CORYNEBACTERIUM PARVUM VACCINE; CYCLOPHOSPHAMIDE; DACARBAZINE; ESTRAMUSTINE; GAMMA INTERFERON; GANGLIOSIDE; IMMUNOMODULATING AGENT; INTERLEUKIN 2; LEVAMISOLE; MEGESTROL ACETATE; METHISOPRINOL; METHYLPHENIDATE; METOCLOPRAMIDE; PACLITAXEL; RETINOIC ACID; SEMUSTINE; THYMOSTIMULIN; TUMOR VACCINE; VINBLASTINE; VINCRISTINE; VINDESINE;

BEAM THERAPY; BONE MARROW TRANSPLANTATION; CANCER ADJUVANT THERAPY; CANCER SURGERY; CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; DRUG TOXICITY; FATIGUE; HUMAN; HYPERTHERMIC THERAPY; IMMUNOTHERAPY; INTRAMUSCULAR DRUG ADMINISTRATION; MELANOMA; META ANALYSIS; METASTASIS; METHODOLOGY; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030925845     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199703000-00015     Document Type: Review

References (120)

1. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 1996, 14:7-17. This landmark report documents the results of the first trial to show a convincing benefit for adjuvant therapy (high-dose Interferon alfa-2b) on both relapse-free and overall survival in stage IIB and III melanoma.
2. Balch CM, Buzaid AC: Finally, a successful adjuvant therapy for high-risk melanoma. J Clin Oncol 1996, 14:1-3. This editorial, accompanying the Kirkwood et al. (J Clin Oncol 1996, 14:7-17) article, highlights the strengths and weaknesses of the Eastern Cooperative Oncology Group trial and provides suggestions for the treatment of high-risk melanoma patients.
3. Balch CM, Buzaid AC: Finally, a successful adjuvant therapy for high-risk melanoma. J Clin Oncol 1996, 14:1-3. This editorial, accompanying the Kirkwood et al. (J Clin Oncol 1996, 14:7-17) article, highlights the strengths and weaknesses of the Eastern Cooperative Oncology Group trial and provides suggestions for the treatment of high-risk melanoma patients.
4. Nathanson L: Interferon adjuvant therapy of melanoma. Cancer 1996, 78:944-947.
5. Balch CM: How patient referral bias can confuse interpretation of clinical results: elective lymph node dissections at the Sydney Melanoma Unit. J Am Coll Surg 1995, 180:490-492. This article explores how retrospective reviews can yield misleading or erroneous results, in this case indicating a favorable impact of elective lymph node dissection when none in fact may have existed.
6. Spitler LE: A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. J Clin Oncol 1991, 9:736-740.
7. Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D, Robinson WA, Flaherty LE, Richards JM, Bartolucci AA, Rosen L: A phase III randomized, double-blind, multiinstitutional trial of vaccinia melanoma oncolysate: active specific immunotherapy for patients with stage II melanoma. Cancer 1995, 75:34-42.
8. Cascinelli N, Bufalino R, Morabito A, Mackie R: Results of adjuvant interferon study in WHO melanoma programme [letter]. Lancet 1994, 343:913-914.
9. Cascinelli N: Evaluation of efficacy of adjuvant rIFNα 2a in melanoma patients with regional node metastases. Proc Am Soc Clin Oncol 1995, 14:410.
10. Morton DL, Eilber FR, Malmgren RA, Wood WC: Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 1970, 68:158-164.
11. Eilber FR, Morton DL, Holmes EC, Sparks FC, Ramming KP: Adjuvant immunotherapy with BCG in treatment of regional lymph node metastases from malignant melanoma. N Engl J Med 1976, 294:237-240.
12. Gutterman JU, Richman SP, McBride CM, Burgess MA, Bartold SL, Kennedy A, Gehan EA, Mavligit G, Hersh EM: Immunotherapy for recurrent malignant melanoma: efficacy of BCG in prolonging the postoperative disease-free interval and survival. Recent Results Cancer Res 1979, 68:359-362.
13. Rosenberg SA, Rapp H, Terry W, Zbar B, Costa J, Seipp C, Simon R: Intralesional BCG therapy of patients with primary stage I melanoma. In Immunotherapy of Human Cancer. Edited by Terry WD, Rosenberg SA, New York: Excerpta Medica; 1982:239.
14. Ariyan S, Kirkwood JM, Mitchell MS, Nordlund JJ, Lerner AB, Papac RJ: Intralymphatic and regional surgical adjuvant immunotherapy in high-risk melanoma of the extremities. Surgery 1982, 92:459-463.
15. Cunningham TJ, Schoenfeld D, Nathanson L, Wolter J, Patterson W, Cohen M, Kuperminc M, Carbone PP: A controlled ECOG study of adjuvant therapy in patients with stage I & II malignant melanoma. In Adjuvant Therapy of Cancer II. Edited by Jones SE, Salmon SE. New York: Grune & Stratton; 1979:507.
16. Kaiser LR, Burk MW, Morton DL: Adjuvant therapy for malignant melanoma. Surg Clin North Am 1981, 61:1249-1257.
17. Pinsky CM, Oettgen HF: Surgical adjuvant therapy for malignant melanoma. Surg Clin North Am 1981, 61:1259-1266.
18. Fisher RI, Terry WD, Hodes RJ, Rosenberg SA, Makuch R, Gordon HG, Fisher SG: Adjuvant immunotherapy or chemotherapy for malignant melanoma: preliminary report of the National Cancer Institute randomized clinical trial. Surg Clin North Am 1981, 61:1267-1277.
19. Veronesi U, Adamus J, Aubert C, Bajetta E, Beretta G, Bonadonna G, Bufalino R, Cascinelli N, Cocconi G, Durand J, et al.: A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 1982, 307:913-916.
20. Paterson AHG, Willans DJ, Jerry LM, Hanson J, McPherson TA: Adjuvant BCG immunotherapy for malignant melanoma. Can Med Assoc J 1984, 131:744-748.
21. Karakousis CP, Emrich LJ: Adjuvant treatment of malignant melanoma with DTIC + Estracyt or BCG. J Surg Oncol 1987, 36:235-238.
22. Quirt IC, Shelley WE, Pater JL, Bodurtha AJ, McCulloch PB, McPherson TA, Paterson AHG, Prentice R, Silver HKB, Willan AR, et al.: Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1991, 9:729-735.
23. Czarnetzki BM, Macher E, Suciu S, Thomas D, Steerenberg PA, Rümke P: Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC protocol 18781 ). Eur J Cancer 1993, 29A:1237-1242.
24. McLean IW, Berd D, Mastrangelo MJ, Shields JA, Davidorf FH, Grever M, Makley TA, Gamel JW: A randomized study of methanol-extraction residue of bacille Calmette-Guerin as postsurgical adjuvant therapy of uveal melanoma. Am J Ophthalmol 1990, 110:522-526.
25. Balch CM, Smalley RV, Bartolucci AA, Burns D, Presant CA, Durant JR: A randomized prospective clinical trial of adjuvant C. parvum immunotherapy in 260 patients with clinically localized melanoma (stage I): prognostic factors analysis and preliminary results of immunotherapy. Cancer 1982, 49:1079-1084.
26. Thatcher N, Mene A, Banerjee SS, Craig P, Gleave N, Orton C: Randomized study of Corynebacterium parvum adjuvant therapy following surgery for (stage II) malignant melanoma. Br J Surg 1986, 73:111-115.
27. Lipton A, Harvey HA, Lawrence B, Gottlieb R, Kukrika M, Dixon R, Graham W, Miller S, Heckard R, Schelzel D, et al.: Corynebacterium parvum versus BCG adjuvant therapy in human malignant melanoma. Cancer 1983, 51:57-60.
28. Lipton A, Harvey HA, Balch CM, Antle CE, Heckard R, Bartolucci AA: Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma. J Clin Oncol 1991, 9:1151-1156.
29. Stevenson HC, Green I, Hamilton JM, Calabro BA, Parkinson DR: Levamisole: known effects on the immune system, clinical results, and future applications to the treatment of cancer. J Clin Oncol 1991, 9:2052-2066.
30. Loutfi A, Shakr A, Jerry M, Hanley J, Shibata HR: Double blind randomized prospective trial of levamisole/placebo in stage I cutaneous malignant melanoma. Clin Invest Med 1987, 10:325-328.
31. Lejeune FJ, Macher E, Kleeberg U, Rumke P, Prade M, Thomas D, Suciu S: An assessment of DTIC versus levamisole or placebo in the treatment of high risk stage I patients after surgical removal of a primary melanoma of the skin: a phase III adjuvant study: EORTC protocol 18761. Eur J Cancer Clin Oncol 1988, 24:S81-S90.
32. Lawrence HS: The transfer in humans of delayed skin sensitivity to streptococcal M substance and to tuberculin with disrupted leucocytes. J Clin Invest 1955, 34:219-230.
33. Bukowski RM, Deodhar S, Hewlett JS, Greenstreet R: Randomized controlled trial of transfer factor in stage II malignant melanoma. Cancer 1983, 51:269-272.
34. Miller LL, Spitler LE, Allen RE, Minor DR: A randomized, double blind, placebo-controlled trial of transfer factor as adjuvant therapy for melanoma. Cancer 1988, 61:1543-1549.
35. Martinez J, Miller L, Allen R, Spitler L: A randomized trial of isoprinosine as surgical adjuvant therapy of melanoma: final report Proc Am Assoc Cancer Res 1990, 31:203.
36. Khayat D, Pompidou A, Soubrane C, Lauret P, Bazex JA, Verola O, Bruley JC, Joly P, Marguery MC, Zylberait P, et al.: Results of two successive randomized prospective studies of nonspecific adjuvant immunotherapy of thin malignant melanoma. Fourth International Congress on Anticancer Chemotherapy. Paris: Congress on Anticancer Chemotherapy; 1993:118.
37. Azizi E, Brenner HJ, Shoham J: Postsurgical adjuvant treatment of malignant melanoma patients by the thymic factor thymostimulin. Arzneimittelforschung 1984, 34:1043-1046.
38. Bernengo MG, Doveil GC, Lisa F, Meregalli M, Novelli M, Zina G: The immunological profile of melanoma and the role of adjuvant thymostimulin immunotherapy in stage I patients. In Thymic Factor Therapy: Serono Symposia Publications. New York: Raven Press; 1984:329-339.
39. Norris RW, Byrom NA, Nagvekar NM, Dean AJ, Mahaffey P, Hobbs JR: Thymostimulin plus surgery in the treatment of primary truncal malignant melanoma: preliminary results of a U.K. multi-centre clinical trial. In Thymic Factor Therapy: Serono Symposia Publications. New York: Raven Press; 1984:341-348.
40. Mclllmurray MB, Embleton MJ, Reeves WG, Langman MJS, Deane M: Controlled trial of active immunotherapy in management of stage IIB malignant melanoma. BMJ 1977, 1(6060):540-542.
41. McIllmurray MB, Reeves WG, Langman MJS, Deane M, Embleton MJ: Active immunotherapy in melanoma [letter]. BMJ 1978, 1(6112):579.
42. Aranha GV, McKhann CF, Grage TB, Gunnarsson A, Simmons RL: Adjuvant immunotherapy of malignant melanoma. Cancer 1979, 43:1297-1303.
43. Galligioni E, Quaia M, Merlo A, Carbone A, Spada A, Favaro D, Santarosa M, Sacco C, Talamini R: Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and Bacillus Calmette Guérin: five-year results of a prospective randomized study. Cancer 1996, 77:2560-2566. In one of the largest studies of autologous tumor vaccines to date, the authors randomized 120 patients with resected renal cell carcinomas to observation or autologous tumor vaccination using BCG as an adjuvant There was no difference in 5-year disease-free or overall survival between the treatment and the control groups.
44. McCulloch PB, Dent PB, Blajchman M, Muirhead WM, Price RA: Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival. Can Med Assoc J 1977, 117:33-36.
45. Berd D, Maguire HC, Mastrangelo MJ: Treatment of human melanoma with a hapten-modified autologous vaccine. Ann N Y A cad Sci 1993, 690:147-152.
46. Berd D, Maguire HC, Nathan FN, Schucter LM, Bloome E, Mastrangelo MJ: Autologous, DNP-modified vaccine as post-surgical adjuvant treatment of stages III and IV melanoma. Proc Am Soc Clin Oncol 1996, 15:554.
47. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc Natl Acad Sci U S A 1993, 90:3539-3543.
48. Arca MJ, Krauss JC, Strome SE, Cameron MJ, Chang AE: Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes. Cancer Immunol Immunother 1996, 42:237-245.
49. Morton DL: Adjuvant immunotherapy of malignant melanoma: status of clinical trials at UCLA. Int J Immunother 1986, 2:31-36.
50. Hedley DW, McElwain TJ, Currie GA: Specific active immunotherapy does not prolong survival in surgically treated patients with stage IIB melanoma and may promote early recurrence. Br J Cancer 1978, 37:491-496.
51. Schultz N, Oratz R, Chen D, Zeleniuch-Jacquotte A, Abeles G, Bystryn JC: Effect of DETOX as an adjuvant for melanoma vaccine. Vaccine 1995, 13:503-508.
52. Helling F, Zhang A, Shang A, Adluri S, Calves M, Koganty R, Longenecker BM, Yao TJ, Oettgen HF, Livingston PO: GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 1995, 55:2783-2788.
53. Oratz R, Dugan M, Roses DF, Harris MN, Speyer JL, Hochster H, Weissman J, Henn M, Bystryn JC: Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine. Cancer Res 1991, 51:3643-3647.
54. Hoon DSB, Foshag LJ, Nizze AS, Bohman R, Morton DL: Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide. Cancer Res 1990, 50:5358-5364.
55. Cassel WA, Murray DR, Phillips HS: A phase II study on the postsurgical management of stage II malignant melanoma with a Newcastle disease virus oncolysate. Cancer 1983, 52:856-860.
56. Hershey P, Coates P, McCarthy WH: Active immunotherapy following surgical removal of high risk melanoma: present status and future prospects. SBT93: Society for Biological Therapy, Proceedings of 8th Annual Scientific Meeting. Biological Therapy of Cancer-VIII. Nashville: Society for Biological Therapy: 1993:24.
57. Livingston PO, Wong GYC, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C, Calves MJ, Helling F, Ritter G, Oettgen HF, Old LJ: Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with QM2 ganglioside. J Clin Oncol 1994, 12:1036-1044.
58. Hershey P: Ganglioside antigens in tissue sections of skin, naevi, and melanoma: implications for treatment of melanoma. In Melanoma Research: Genetics, Growth Factors, Metasteses, and Antigens. Edited by Nathanson L. Boston: Kluwer Academic Publishers; 1991:137.
59. Hamilton WB, Helling F, Lloyd KO, Livingston PO: Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography. Int J Cancer 1993, 53:566-573.
60. Tai T, Cahan LD, Tsuchida T, Saxton RE, Irie RF, Morton DL: Immunogenicity of melanoma-associated gangliosides in cancer patients, Int J Cancer 1985, 35:607-612.
61. Minasian LM, Yao TJ, Steffens TA, Scheinberg DA, Williams L, Riedel E, Houghton AN, Chapman PB: A phase 1 study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma. Cancer 1995, 75:2251-2257.
62. Livingston PO, Ritter G, Srivastava P, Padavan M, Calves MJ, Oettgen HF, Old LJ: Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res 1989, 49:7045-7050.
63. Takahashi T, Chang C, Morton DL, Irie RF: IgM antibodies to ganglioside GM3 and GD3 induced by active immunization correlated with survival in melanoma patients. Proc Am Assoc Cancer Res 1995, 36:485.
64. Chatterjee MB, Foon KA, Köhler H: Idiotypic antibody immunotherapy of cancer. Cancer Immunol Immunother 1994, 38:75-82.
65. Mittelman A, Wang X, Matsumoto K, Ferrone S: Antiantiidiotypic response and clinical course of the disease in patients with malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Hybridoma 1995, 14:175-181.
66. Saleh MN, Stapleton JD, Khazaeli MB, LoBuglio AF: Generation of a human anti-idiotypic antibody that mimics the GD2 antigen. J Immunol 1993, 151:3390-3398.
67. McCaffery M, Yao TJ, Williams L, Livingston PO, Houghton AN, Chapman PB: Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant. Clin Cancer Res 1996, 2:679-686. This trial demonstrated the ability of an anti-anti-GD3 antibody (anti-idiotypic antibody) to induce anti-GD3 antibody production in patients with melanoma.
68. Robbins PF, Kawakami Y: Human tumor antigens recognized by T cells. Curr Opin Immunol 1996, 8:628-636. The authors review the HLA-restricted tumor antigens that have been described and the T-cell epitopes that have been identified. Melanoma-associated antigens may be generated by severa: mechanisms, including transcription of normal, nonmutated genes, translation of alternative open reading frames, mutations of widely expressed genes, incomplete splicing, transcription from cryptic promoters, or posttranslational modification. Many of these antigens are currently being evaluated in clinical trials as targets for adjuvant or combination therapy for melanoma patients.
69. Marincola FM, Shamamian P, Rivoltini L, Salgaller M, Cormier J, Restifo NP, Simonis TB, Venzon D, White DE, Parkinson DR: HLA associations in the antitumor response against malignant melanoma. J Immunother 1996, 18:242-252.
70. Creagan ET, Ingle JN, Schutt AJ, Schaid DJ: A prospective, randomized controlled trial of megestrol acetate among high-risk patients with resected malignant melanoma. Am J Clin Oncol 1989, 12:152-155.
71. Meyskens FL Jr, Liu PY, Tuthill RJ, Sondak VK, Fletcher WS, Jewell WR, Samlowski W, Balcerzak SP, Rector DJ, Noyes RD, et al.: Randomized trial of vitamin A versus observation as adjuvant therapy in high risk primary malignant melanoma: a Southwest Oncology Group study. J Clin Oncol 1994, 12:2060-2065.
72. Lotan R, Hendrix MJC, Lippman SM: Retinoids in the management of melanoma. In Retinoids in Cutaneous Malignancy. Edited by Marks R. London: Blackwell Scientific; 1991:133.
73. Meyskens FL Jr, Booth AE, Goff P, Moon TE: Randomized trial of BCG ± vitamin A for stages I and II cutaneous malignant melanoma. In Adjuvant Therapy of Cancer V. Edited by Salmon SE. New York: Grune & Stratton: 1987:665.
74. Thornes RD, Daly L, Lynch G, Breslin B, Browne H, Browne HY, Corrigan T, Daly P, Edwards G, Gaffney E, et al.: Treatment with coumarin to prevent or delay recurrence of malignant melanoma. J Cancer Res Clin Oncol 1994, 120:S32-S34.
75. Houghton AN, Legha S, Bajorin DF: Chemotherapy for metastatic melanoma. In Cutaneous Melanoma edn 2. Edited by Balch CM, Houghton AN, Milton GW, Sober AJ, Soong S. Philadelphia: J.B. Lippincott; 1992:498.
76. Hill GJ II, Moss SE, Golomb FM, Grage TB, Fletcher WS, Minton JP, Krementz ET: DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) Surgical Adjuvant Study COG protocol 7040. Cancer 1981, 47:2556-2562.
77. Quirt IC, DeBoer G, Kersey PA, Baker MA, Bodurtha AJ, Norvell ST, Gapski J, King MH, Cowan DH, From L, et al.: Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases. Can Med Assoc J 1983, 128:929-933.
78. Wood WC, Cosimi AB, Carey RW, Kaufman SD: Randomized trial of adjuvant therapy for "high-risk" primary malignant melanoma. Surgery 1978, 83:677-681.
79. Knost JA, Reynolds V, Greco FA, Oldham RK: Adjuvant chemoimmunotherapy stage I/II malignant melanoma. J Surg Oncol 1982, 19:165-170.
80. Sterchi JM, Wells HB, Case LD, Spurr CL, White DR, Richards F, Muss HB, Jackson DV, Stuart JJ, Cooper MR: A randomized trial of adjuvant chemotherapy and immunotherapy in stage I and II cutaneous melanoma: an interim report. Cancer 1985, 55:707-712.
81. Castel T, Estapé J, Vin̄olas N, Mascarö JM, Castro J, Vilalta A, Gratacos R, Daniels M, Palou J, Grau JJ, Iranzo P: Adjuvant treatment in stage I and II malignant melanoma: a randomized trial between chemoimmunotherapy and immunotherapy. Dermatologica 1991, 183:25-30.
82. Balch CM, Murray D, Presant C, Bartolucci AA: Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma. Surgery 1984, 95:454-459.
83. Karakousis CP, Didolkar MS, Lopez R, Baffi R, Moore R, Holyoke ED: Chemoimmunotherapy (DTIC and Corynebacterium parvum) as adjuvant treatment in malignant melanoma. Cancer Treat Rev 1979, 63:1739-1743.
84. Banzet P, Jacquillat C, Civatte J, Puissant A, Maral J, Chastang C, Israel L, Belaich S, Jourdain JC, Weil M, Auclerc G: Adjuvant chemotherapy in the management of primary malignant melanoma. Cancer 1978, 41:1240-1248.
85. Quagliana J, Tranum B, Neidhardt J, Gagliano R: Adjuvant chemotherapy with BCNU, Hydrea and DTIC (BHD) with or without immunotherapy (BCG) in high risk melanoma patients: a SWOG study. Proc Am Assoc Cancer Res 1980, 21:399.
86. Misset JL, Delgado M, De Vassal F, Mathe G, Serrou B, Jeanne C, Guerrin J, Plagne R, Schneider M, Le Mevel B, Metz R: Immunotherapy or chemo-immunotherapy as adjuvant treatment for malignant melanoma: a G.I.F. trial. In Adjuvant Therapy of Cancer III. Edited by Salmon SE, Jones SE, New York: Grune & Stratton; 1981:225.
87. Kerin MJ, Gillen P, Monson JRT, Wilkie J, Keane FBV, Tanner WA: Results of a prospective randomized trial using DTIC and Interferon as adjuvant therapy for stage I malignant melanoma. Eur J Surg Oncol 1995, 21:548-550.
88. Karakousis C, Blumenson L: Adjuvant chemotherapy with a nitrosourea based protocol in advanced malignant melanoma. Eur J Cancer 1993, 29A:1831-1835.
89. Hansson J, Ringborg U, Lagerlof B, Strander H: Adjuvant chemotherapy of malignant melanoma: a pilot study. Am J Clin Oncol 1985, 8:47-50.
90. Jacquillat C, Banzet P, Civatte J, Puissant A, Cottenot F, Israel L, Belaich S, Chastang CL, Maral J: Adjuvant chemotherapy or chemoimmunotherapy in the management of primary malignant melanoma of level III, IV, or V. Recent Results Cancer Res 1979, 68:346-358.
91. Tranum BL, Dixon D, Quagliana J, Neidhart J, Balcerzak SP, Costanzi JH, Fabian CJ, Neilan B, Maloney T, O'Bryan RM, Groppe C: Lack of benefit of adjunctive chemotherapy in stage I malignant melanoma: a Southwest Oncology Group Study. Cancer Treat Rep 1987, 71:643-644.
92. Buzaid AC, Legha S, Bedikian A, Eton O, Papadopoulos N, Plager C, Ross M, Lee J, Mansfield P, Strom E, et al.: Neoadjuvant biochemotherapy in melanoma patients (pts) with local regional metastases (LRM). Proc Am Soc Clin Oncol 1996, 15:434.
93. Meisenberg BR, Ross M, Vredenburgh JJ, Jones R, Shpall EJ, Seigler HF, Coniglio DM, Wu K, Peters WP: Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node-positive malignant melanoma. J Natl Cancer Inst 1993, 85:1080-1085.
94. Herlyn M, Guerry D, Koprowski H: Recombinant γ-interferon induces changes in expression and shedding of antigens associated with normal human melanocytes, nevus cells, and primary and metastatic melanoma cells. J Immunol 1985, 134:4226-4230.
95. Kurzrock R, Rosenblum MG, Sherwin SA, Rios A, Talpaz M, Quesada JR, Gutterman JU: Pharmacokinetics, single-dose tolerance and biological activity of recombinant γ interferon in cancer patients. Cancer Res 1985, 45:2866-2872.
96. Maluish AE, Urba WJ, Longo DL, Overton WR, Coggin D, Crisp ER, Williams R, Sherwin SA, Gordon K, Steis RG: The determination of an immunologically active dose of interferon-gamma in patients with melanoma. J Clin Oncol 1988, 6:434-445.
97. Schiller JH, Pugh M, Kirkwood JM, Karp D, Larson M, Borden E: Eastern Cooperative Group trial of interferon gamma in metastatic melanoma: an innovative study design. Clin Cancer Res 1996, 2:29-36.
98. Jaffe HS, Herberman RB: Rationale for recombinant human interferon-gamma adjuvant immunotherapy for cancer. J Natl Cancer Inst 1988, 80:616-618.
99. Meyskens FL Jr, Kopecky K, Taylor CW, Noyes RD, Tuthill RJ, Hersh EM, Feun LG, Doroshow JH, Flaherty LE, Sondak VK: Randomized trial of adjuvant human interferon γ versus observation in high-risk cutaneous melanoma. J Natl Cancer Inst 1995, 87:1710-1713.
100. Meyskens FL Jr, Kopecky K, Samson M, Hersh E, Macdonald J, Jaffe H, Crowley J, Coltman C: Recombinant human interferon gamma: adverse effects in high-risk stage I and II cutaneous malignant melanoma [Letter]. J Natl Cancer Inst 1990, 82:1071.
101. Osoba D, Zee B, Sadura A, Pater J, Quirt I: Measurement of quality of life in an adjuvant trial of gamma interferon versus levamisole in malignant melanoma. In Adjuvant Therapy of Cancer VII. Edited by Salmon SE. Philadelphia: J.B. Lippincott; 1993:412.
102. Parkinson DR, Houghton AN, Hersey P, Borden EC: Biologic therapy for melanoma. In Cutaneous Melanoma edn 2. Edited by Balch CM, Houghton AN, Milton GW, Sober AJ, Soong S. Philadelphia: J.B. Lippincott; 1992:522.
103. Agarawal SS, Kirkwood JM: Interferons in melanoma. Curr Opin Oncol 1996, 8:167-174. The authors review the role of interferons in the therapy for melanoma. Interferon alfa produces objective responses in approximately 16% of patients with metastatic melanoma, of which about one third are complete responses Potential mechanisms of action are also discussed.
104. Kokoschka EM, Trautinger F, Knobler RM, Pohl-Markl H, Micksche M: Long-term adjuvant therapy of high-risk malignant melanoma with interferon α2b. J Invest Dermatol 1990, 95:S193-S197.
105. Creagan ET, Dalton RJ, Ahmann DL, Jung S-H, Morton RF, Langdon RM Jr, Kugler J, Rodrigue LJ: Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995, 13:2776-2783. This randomized trial evaluated adjuvant therapy with a 3-month course of high-dose intramuscular interferon alfa-2a compared with observation in 262 patients with stage II and III melanoma. Overall, there was no significant difference in disease-free or overall survival between the treatment and control arms. Node-positive patients had a statistically significant improvement in disease-free survival in a multivariate analysis.
106. Cole BF, Gelber RD, Kirkwood JM, Goldhirsch A, Barylak E, Borden E: Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1996, 14:2666-2673. Using quality-adjusted time without symptoms or toxicity methodology, patients with stage III melanoma randomized to high-dose interferon on the ECOG E1684 trial were found to have more time without symptoms or toxicity than the observation group.
107. Grob JJ, Dreno B, Delaunay M, Chastang C, Guillot B, Cupissol B, Souteyrand P, Sassolas B, Cesarini JP, Thivolet J, et al.: Results of the French multicenter trial on adjuvant therapy with Interferon alfa-2a in resected primary melanoma (> 1.5 mm). Proc Am Soc Clin Oncol 1996, 15:437.
108. Schmidt-Ullrich RK, Johnson CR: Role of radiotherapy and hyperthermia in the management of malignant melanoma. Semin Surg Oncol 1996, 12:407-415.
109. Ang KK, Peters LJ, Weber RS, Morrison WH, Frankenthaler RA, Garden AS, Goepfert H, Ha CS, Byers RM: Postoperative radiotherapy for cutaneous melanoma of the head and neck region. Int J Radiat Oncol Biol Phys 1994, 30:795-798.
110. Creagan ET, Cupps RE, Ivins JC, Pritchard DJ, Sim FH, Soule EH, O'Fallon JR: Adjuvant radiation therapy in the treatment of regional nodal metastases from malignant melanoma: a randomized prospective study. Cancer 1978, 42:2206-2210.
111. Kirkwood JM, Earle JD, Fine SL, Hawkins BS, Straatsma BR, Mowery RL: Five-year progress report: the Collaborative Ocular Melanoma Study. Proc Am Soc Clin Oncol 1992, 11:349.
112. Cumberlin R, De Moss E, Lassus M, Friedman M: Isolation perfusion for malignant melanoma of the extremity: a review. J Clin Oncol 1985, 3:1022-1031.
113. Lienard D, Ewalenko P, Delmotte J-J, Renard N, Lejeune FJ: High-dose recombinant tumor necrosis factor alpha in combination with Interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992, 10:52-60.
114. Ghussen F, Krüger I, Smalley RV, Groth W: Hyperthermic perfusion with chemotherapy for melanoma of the extremities. World J Surg 1989, 13:598-602.
115. Hafström L, Rudenstam C-M, Blomquist E, Ingvar C, Jönsson P-E, Lagerlöf B, Lindholm C, Ringborg U, Westman G, Östrup L: Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. J Clin Oncol 1991, 9:2091-2094.
116. Schraffordt-Koops H, Vaglini M, Kroon B, Thomson J, Göhl J, Eggermont A, Di Filippo F, Lejeune F: Value of prophylactic isolated limb perfusion (ILP) for stage I high risk malignant melanoma: a randomized phase III trial. Fourth World Conference on Melanoma. Syndey, Australia: June 10-14, 1997.
117. Miller RL, Steis RG, Clark JW, Smith JW 2d, Crum E, McKnight JE, Hawkins MJ, Jones MJ, Longo DL, Urba WJ: Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma. Cancer Res 1989, 49:1871-1876.
118. Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU: Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986, 4:234-243.
119. Rabinowich H, Banks M, Reichert TE, Logan TF, Kirkwood JM, Whiteside TL: Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. Clin Cancer Res 1996, 2:1263-1274. Patients with cancer have been reported to have altered expression and function of signaling molecules in T and natural killer cells. The authors found decreased levels of CD3-ζ expression in T cells from tumor-draining lymph nodes of melanoma patients. Melanoma patients treated with interleukin-2 immunotherapy who achieved clinical responses showed normalization of the CD3-ζ expression in peripheral blood T cells.
120. 2 microglobulin, a key component of the major histocompatibility complex molecule, may be a mechanism whereby tumor cells escape immune recognition and destruction.